Key terms
About EQ
Equillium, Inc. engages in the development of products for severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. Its product pipeline includes EQ001, which is a monoclonal antibody that selectively targets the novel immune checkpoint receptor CD6. The company was founded by Daniel Mark Bradbury, Bruce D. Steel, and Stephen Connelly in March, 2017 and is headquartered in La Jolla, CA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest EQ news
Apr 03
8:03am ET
Equillium reports inducement grant under Nasdaq listing rule
Apr 03
1:45am ET
Buy Rating Affirmed for Equillium on Strong Clinical Data and Potential Financial Upsides
Apr 02
6:27am ET
Buy Rating Reaffirmed for Equillium on Strong Itolizumab Trial Results and Positive Financial Outlook
Apr 02
6:12am ET
Equillium price target raised to $5 from $4 at H.C. Wainwright
Apr 01
8:07am ET
Equillium announces topline data from Type B portion of EQUALISE study
Mar 25
4:05pm ET
Equillium reports Q4 EPS (7c) vs. 8c last year
Mar 08
4:13pm ET
Equillium Inc Announces New Principal Accounting Officer and 2024 Inducement Plan
Feb 24
10:18am ET
Equillium Inc Announces $21.95M Common Stock Offering
Feb 22
10:59am ET
Biotech Alert: Searches spiking for these stocks today
Feb 22
6:25am ET
Equillium Inc Regains Nasdaq Compliance with Bid Price
Feb 09
11:12am ET
Biotech Alert: Searches spiking for these stocks today
Feb 08
11:40am ET
Biotech Alert: Searches spiking for these stocks today
No recent news articles are available for EQ
No recent press releases are available for EQ
EQ Financials
Key terms
Ad Feedback
EQ Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
EQ Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
